Abeona Therapeutics Inc. (ABEO) stock
ABEONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/3039% below fair value
$2.42+0.13 (+5.68%)
Close on Nov 13, 2026Market cap $138.39MP/E –Yield –
Abeona Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Abeona Therapeutics's total debt was $11.85M at Sep 30, 2026. For fiscal 2025 it was $20.04M, up 5.7% from the year before. The highest annual figure on record is $20.04M in fiscal 2025.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.04M | +5.7% |
| FY2024 | Dec 31, 2024 | $18.96M | – |
| FY2015 | Dec 31, 2015 | $0 | -100.0% |
| FY2014 | Dec 31, 2014 | $400.00K | – |
| FY2013 | Dec 31, 2013 | $0 | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $11.85M | -40.0% |
| Q2 FY2026 | Jun 30, 2026 | $14.99M | -23.4% |
| Q1 FY2026 | Mar 31, 2026 | $18.09M | -6.2% |
| Q4 FY2025 | Dec 31, 2025 | $20.04M | +5.7% |
| Q3 FY2025 | Sep 30, 2025 | $19.75M | +5.9% |
| Q2 FY2025 | Jun 30, 2025 | $19.56M | +6.6% |
| Q1 FY2025 | Mar 31, 2025 | $19.29M | +6.7% |
| Q4 FY2024 | Dec 31, 2024 | $18.96M | – |
| Q3 FY2024 | Sep 30, 2024 | $18.65M | – |
| Q2 FY2024 | Jun 30, 2024 | $18.36M | – |
| Q1 FY2024 | Mar 31, 2024 | $18.08M | – |
See a number that looks wrong?